Who is sponsoring NCT05068232?

NCT05068232 is sponsored by University of Chicago.

What condition does NCT05068232 study?

NCT05068232 studies Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer.

What drugs are being tested in NCT05068232?

Interventions: Ablative Radiation, Durvalumab, Etoposide, Carboplatin.

What is the status of NCT05068232?

NCT05068232 is currently RECRUITING.

Last reviewed 2026-03-04 · How we verify

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

NCT05068232 PHASE2 RECRUITING

This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will help treat your cancer and improve how long you can live with extensive-stage small cell cancer without it getting worse (progression-free survival). Your participation in this research will last about 48 months. Durvalumab along with chemotherapy has been approved by the Food and Drug Administration (FDA) for the treatment of small cell lung cancer along with chemotherapy. This study is testing the addition of radiation to durvalumab and chemotherapy.

Details

Lead sponsor	University of Chicago
Phase	PHASE2
Status	RECRUITING
Enrolment	49
Start date	Fri Aug 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Oct 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Small-cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Lung Cancer

Interventions

Ablative Radiation
Durvalumab
Etoposide
Carboplatin

Countries

United States